Table 3 MiRNA and chemoresistance in prostate cancer.
From: Role of noncoding RNA in drug resistance of prostate cancer
MiRNAs | Expression | Genes and pathways | Drug | Reference |
|---|---|---|---|---|
miR-148a | Down | MSK1 | Paclitaxel | |
miR-199a | Down | YES1 | Paclitaxel | |
miR-34a | Down | JAG1/Notch1 | Paclitaxel | |
miR-375 | Up | SEC23A/YAP1 | Docetaxel | |
miR-323 | Up | P73 | Docetaxel | |
miR-181a | Up | ABCB1 | Docetaxel | |
miR-195 | Down | CLU | Docetaxel | |
miR-27a | Up | P53 | Docetaxel | |
miR-204 | Down | ZEB1 | Docetaxel | |
miR-143 | Down | KRAS | Docetaxel | |
miR-193a-5p | Up | Bach2 | Docetaxel | |
miR-138 | Up | Kindlin-2 | Docetaxel | |
miR-200b | Down | Bmi-1 | Docetaxel | |
miR-205 | Down | RAB27A/LAMP3 | Cisplatin | |
miR-17-92 cluster | Up | AKT pathway | Cisplatin |
